与潜在的他类药物相关的处方级联相关的可修改的他类药物特征
Grace Hsin-Min Wang1, Earl Morris1,2, Scott M Vouri1,2
1Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, Florida, USA.
Pharmacotherapy
|September 29, 2023
概括
高强度他类药物增加了处方级联的风险,而特定的他类药物可以增加或降低这种风险. 选择正确的他类药物强度和药剂对于患者的安全至关重要.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 医疗保健服务研究 医疗服务研究
背景情况:
- 处方级联,即为以前药物的不良事件开出新药的处方,是他类药物治疗中的一个问题.
- 了解可修改的他因特征可以帮助缓解这些级联.
研究的目的:
- 为了确定他类药物的强度和个人他类药物与处方级联的风险较低相关.
- 根据有关他类药物选择的临床决策,尽量减少与不良事件相关的处方.
主要方法:
- 使用MarketScan索赔数据 (2005-2019) 进行高通量序列对称性分析的二次分析.
- 在成年类他类药物发起者中评估了42个他类标记物二,样本大小≥500个 (2007-2018).
- 逻辑回归被用来计算调整的几率比率 (aOR) 用于根据他类药物的强度和代理人开处方级联.
主要成果:
- 高强度他类药物与29 (69%) 处方级联的几率明显增加,包括抗糖尿病药物和阿片类药物.
- 个别的他类药物对34个 (81%) 处方级联的风险产生了不同的影响.
- 例如,与simvastatin相比,阿托瓦斯塔丁启动者的需要药的几率较低.
结论:
- 高强度他类药物与低强度他类药物相比,与处方级联的风险增加有关.
- 单个他类药物的选择会影响两方向处方级联的风险.
- 立方体强度和药剂选择是临床实践中需要考虑的关键可修改因素,以减少处方级联风险.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
691
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
691
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
553
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
553
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
186
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
186
01:26Atherosclerosis III: Management
11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
552
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
552
01:19Pharmacovigilance
876
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
876